X-Vir
X-Vir (Entecavir 0.5/1 mg) — Natco potent NRTI for chronic hepatitis B virus suppression. First-line oral HBV therapy. Strict separation from HIV care needed in co-infection.
✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026
Quick Answer
X-Vir — Entecavir 0.5/1 mg (Natco Pharma). Potent NRTI for chronic hepatitis B. First-line oral HBV therapy alongside tenofovir. 0.5 mg in nucleos(t)ide-naive; 1 mg in lamivudine-experienced. NEVER use as HIV monotherapy in untreated co-infection — selects HIV resistance.
What you get with MedsBase:
- WHO-GMP certified manufacturer
- Discreet plain-envelope packaging
- Worldwide shipping
- Rated by 1,400+ customers (read reviews)
📦 Reshipment Assurance: if your order has not arrived 20 business days after dispatch, we reship it at no extra cost. Read the policy.
Why order from MedsBase
X-Vir ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
Lamivudine and entecavir as monotherapy in untreated HIV/HBV co-infection rapidly select HIV resistance (M184V for lamivudine; integrase mutations for entecavir). Test HIV before starting any HBV monotherapy. If HIV-positive, use a complete ART regimen that covers both viruses (typically TDF or TAF + emtricitabine/lamivudine + third agent).
Abrupt withdrawal of any anti-HBV nucleoside/nucleotide can cause severe acute HBV flare with possible decompensation. Never stop without hepatology supervision and post-stop monitoring.
Frequently Asked Questions
When is monotherapy appropriate?
Lamivudine HBV monotherapy is largely outdated due to resistance development. Entecavir and tenofovir are first-line. Lamivudine remains an option in resource-limited settings, in pregnancy (extensive safety data), or as part of combination therapy.
Cure for HBV?
True cure (HBsAg loss, sometimes called functional cure) is rare with current oral therapy — typically <5% per year. Most patients need long-term/lifelong suppression. Disease activity, fibrosis, and HCC risk reduce dramatically with consistent therapy even without HBsAg clearance.
When can I stop?
Cessation is considered after sustained HBeAg seroconversion + undetectable HBV DNA for ≥12 months in HBeAg-positive disease, or HBsAg loss. Discontinuation should always be specialist-supervised with close monitoring for HBV flare.
HCC monitoring?
All patients with chronic HBV need 6-monthly HCC surveillance with abdominal ultrasound ± AFP, especially if cirrhotic, family history of HCC, or specific demographics (Asian male >40, African >20, persistent inflammation).
Pregnancy?
Tenofovir is preferred for pregnancy (TDF or TAF). Lamivudine is alternative with extensive pregnancy data. Entecavir is generally avoided due to limited pregnancy data.
Drug interactions?
Few major interactions for these renally cleared drugs. Avoid combination with nephrotoxic drugs (NSAIDs chronic, aminoglycosides). Tenofovir + ledipasvir-containing Hep C regimens — monitor renal function.
What if I miss a dose?
Take when you remember if same day; if next day, skip the missed dose. Do not double up. Discuss adherence challenges with your hepatologist — alternative regimens or simplified dosing may be available.
Side effects?
Generally well tolerated. Tenofovir disoproxil: renal tubulopathy, bone density loss long-term. Tenofovir alafenamide: minimal renal/bone impact. Entecavir: rare lactic acidosis. Lamivudine: very well tolerated.
What about HCC after treatment?
HBV-related HCC risk persists even after viral suppression — never stop surveillance just because HBV DNA is undetectable. Cirrhotic patients especially need lifelong 6-monthly USS.
Vaccination?
All household contacts and sexual partners should be tested for HBsAg and HBV-vaccinated if susceptible. Patient should also receive HAV vaccination, pneumococcal, annual influenza, and (after CD4 recovery if HIV co-infected) other indicated vaccines.
Other Antiviral Medications
- Tenvir L — tenofovir + lamivudine — combined HIV/HBV NRTI backbone
- X-Vir — entecavir 0.5/1 mg — first-line HBV monotherapy
- Lamivir HBV — lamivudine 100 mg — older HBV monotherapy
- MyHep — sofosbuvir 400 mg — for HCV
- Zimivir — valacyclovir 500/1000 mg — for HSV
More options in HIV Medication
Ranked by recent MedsBase order volume — what other customers in this category are picking.
| Strength | 0.5 mg, 1 mg |
|---|---|
| Quantity | 30 Tablet/s, 60 Tablet/s, 90 Tablet/s |
| Pharma Form | Tablet/s |
| Manufacturer | Natco Pharma |
| Treatment | HIV infection, Chronic hepatitis B virus (HBV) infection |
| Generic Brand | Entecavir |
X-Vir
Q & A
X-Vir
Related products
Reviews
There are no reviews yet